Description

Product Availability: In Stock (delivery within 2-3 business days, no extra charge for drop-shipping).

Ordering: To place an order via credit card or PO use Add to Cart button (creating an account is not required).

---

Transfection Reagent for NCI-H1299 Cells (Lung Adenocarcinoma Cells, CRL-5803)

• Two component formulation enhances lipid mediated transfection efficiency
• Optimized easy-to-use transfection protocol provided for transfection of siRNA, DNA, mRNA, and microRNA
• Kit includes Transfection Enhancer reagent and recommended transfection protocol
• High transfection efficacy in the presence of serum
• Expand your RNAi application with a reagent optimized for delivery of both siRNA and plasmid
• Reproducible transfection results
• Works well for standard reverse transfection and high-throughput applications
• Download in vitro NCI-H1299 transfection protocol: [PDF]
• Download NCI-H1299 CRISPR/Cas9 transfection protocol: [PDF]
• Download PowerPoint presentation for NCI-H1299 cells transfection kit: [PPT]
• Developed and manufactured by Altogen Biosystems

Transfection Efficiency:

Reagent exhibits at least 91% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.

Transfection Protocol and MSDS:

Download Altogen Biosystems NCI-H1299 Transfection Protocol: [PDF]

Download MSDS: [PDF]

NCI-H1299 Cell Line:

Lung cancer is considered the leading cause of cancer death worldwide among both women and men. It mainly occurs in older people, with an average patient age of 70 years. Less than 2% of all diagnosed patients are younger than 45, per the American Cancer Society (ACS). Furthermore, it is the most preventable cancer, affecting smokers 15 to 30 times more often than people who do not smoke. Many lung cancer patients are resistant to current treatments, including chemotherapy and radiotherapy. The NCI-H1299 cell line was initially established from the lung cells of a 43-year-old Caucasian male patient with non-small cell lung cancer. These cells were derived from the lymph node metastatic site, and exhibit epithelial cell morphology. They lack expression of the p53 protein and have been known to synthesize peptide neuromedin B (NMB). NCI-H1299 are useful for studying lung cancer in humans. Altogen Biosystems offers transfection reagent kits for the NCI-H1299 cell line.

Data:

Figure 1. GAPD mRNA levels were quantified using real-time RT-PCR in the NCI-H1299 cells transfected with siRNAs targeting GAPD or non-silencing siRNA. Forty-eight hours post-transfection, the cells were harvested and analyzed by real-time RT-PCR for GAPD mRNA expression levels. Data were normalized against the 18S rRNA signal. Control samples were either mock-transfected or untreated. Values are normalized to untreated sample. Data are means ± SD (n=5).

Figure 2. Protein expression of GAPDH in NCI-H1299 cells. DNA plasmid expressing GAPDH or siRNA targeting GAPDH were transfected into NCI-H1299 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.

Altogen Biosystems:
Altogen Biosystems manufacturers preoptimized transfection kits for cancer research. Reagents and transfection protocols are optimized for individual cancer cell lines. Altogen Biosystems developed two types of in vivo delivery kits for animal research: Tissue-targeted reagents (delivery into liver, pancreas, and kidney tissues), and in vivo biodistribution reagents (PEG-Liposome, Nanoparticle, Lipid, and Polymer-based kits). Optimized transfection protocols provide efficient intracellular delivery of proteins, DNA, and RNA molecules in vitro and in vivo. Read more about transfection technology at Altogen’s Transfection Resource.

Altogen Research Services:

Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (30+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).

Volume Options:

• 0.5 ml (Catalog #6852)
• 1.5 ml (Catalog #6853)
• 1.5 ml CRISPR (Catalog #2176)
• 8.0 ml (Catalog #7066)

Altogen Biosystems是一家开发和制造用于生命科学研究，药物发现和开发的转染试剂盒的生物技术公司。转染试剂盒针对特定癌细胞系和原代细胞培养进行了优化，可将生物分子有效递送到靶组织中。通过先进的试剂配方和优化的转染方案实现体外（癌细胞系）和体内（动物组织靶向试剂、癌细胞系）递送货物分子，包括质粒DNA，各种类型的RNA（mRNA，siRNA，shRNA，microRNA），蛋白质和小分子研究。 Altogen Biosystems全国代理部分产品列表： 货号 产品 规格 价格（美元） 5030       1703 A204 Transfection Reagent (Rhabdomyosarcoma) 0.5ml 170 1704 A204 Transfection Reagent (Rhabdomyosarcoma) 1.5ml 348 窗体顶端 窗体底端   2101 A204 Transfection Reagent (Rhabdomyosarcoma) 1.5ml CRISPR 548 窗体顶端 窗体底端   7018 A204 Transfection Reagent (Rhabdomyosarcoma) 8.0ml 1044 窗体顶端 窗体底端   1167 A375 Cells Transfection Reagent (CRL-1619) 0.5ml 195 1168 A375 Cells Transfection Reagent (CRL-1620) 1.5ml 427 2102 A375 Cells Transfection Reagent (CRL-1621) 1.5ml CRISPR 627 1169 A375 Cells Transfection Reagent (CRL-1622) 8.0ml 1281 5030 Nanoparticle In Vivo Transfection Reagent 0.5 ml - 10 injections  445 5010 LIPID In Vivo Transfection Reagent 0.5 ml - 10 injections 405 5040 PEG-Liposome In Vivo Transfection Reagent 0.5 ml - 10 injections 465 5020 POLYMER In Vivo Transfection Reagent 0.5 ml - 10 injections 425 5050 Pancreas In Vivo Transfection Kit 0.5 ml - 10 injections  495 5060 Liver In Vivo Transfection Kit 0.5 ml - 10 injections  495 5070 Kidney In Vivo Transfection Kit 0.5 ml - 10 injections  495 1721 BMS2 Transfection Reagent (Bone Marrow Cells) 0.5 ml  231 6345 C6 Transfection Reagent (Glioma Cells, CCL-107) 0.5 ml  199 6803 DLD-1 Transfection Reagent (Colon Cancer, CCL-221) 0.5 ml  201 1775 HUH-7 Transfection Reagent (Liver Cancer Cells) 0.5 ml  179